Haifa, Israel, November 18, 2026
Biostream, a company developing urine-based biomarker diagnostic technologies for neurological conditions, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its investigational urine test designed to aid the diagnosis of idiopathic normal pressure hydrocephalus (iNPH). The designation was granted on November 12, 2026, and represents an important regulatory milestone for the company’s non-invasive diagnostic approach. The test is designed to measure a panel of proteins in urine and apply a proprietary algorithm to generate a probability score that can help healthcare professionals identify patients who may have iNPH. It is intended to support the differentiation of this potentially treatable neurological condition from Alzheimer’s disease and other neurodegenerative disorders in patients aged 60 and older who present with suggestive symptoms. The announcement highlights the potential of urinary biomarkers and machine learning to support earlier and more accessible neurological diagnosis.
Urine-Based Biomarker Test Targets Normal Pressure Hydrocephalus
Normal pressure hydrocephalus (NPH) is a neurological condition associated with the accumulation of cerebrospinal fluid (CSF) in the brain’s ventricles. The condition can cause three characteristic symptoms: difficulty walking, cognitive impairment and loss of bladder control. When the condition has no identifiable underlying cause, it is referred to as idiopathic normal pressure hydrocephalus. Although its symptoms can resemble those of Alzheimer’s disease, Parkinson’s disease and other age-related neurological disorders, iNPH is important to recognise because it may be treatable. In selected patients, shunt surgery can drain excess cerebrospinal fluid and improve symptoms, particularly when the condition is identified and treated early. However, diagnosis can be challenging because symptoms frequently overlap with other neurological conditions. Current diagnostic evaluation generally involves clinical assessments, brain imaging and procedures such as the lumbar tap test, which assesses changes following the removal of cerebrospinal fluid. These investigations may require specialist facilities and can be invasive. Biostream’s urine-based test is being developed to provide an additional source of objective biological information to support the diagnostic process.
Protein Analysis and Machine Learning Support Diagnosis
Biostream’s investigational iNPH test combines urinary proteomics with a proprietary machine-learning algorithm. The technology measures a panel of proteins present in a urine sample and analyses the results to generate a probability score associated with the likelihood of iNPH. The intended purpose is to help clinicians distinguish patients who may have the condition from those whose symptoms could be associated with Alzheimer’s disease or other neurodegenerative disorders. The test is designed for use alongside a healthcare professional’s clinical evaluation rather than as a standalone diagnostic method. Its non-invasive sample collection approach could offer practical advantages compared with diagnostic procedures that require cerebrospinal fluid sampling. The company aims to provide clinicians with additional biological evidence that may help determine which patients should undergo further neurological assessment. The intended patient population includes individuals aged 60 and older who have symptoms suggestive of normal pressure hydrocephalus. The development programme reflects growing interest in using protein biomarkers and artificial intelligence-based analytical methods to support the diagnosis of complex neurological diseases. However, the test’s diagnostic performance, clinical utility and ability to improve patient outcomes must still be established through prospective clinical validation.
FDA Breakthrough Designation Supports Clinical Development
The FDA Breakthrough Devices Program is intended to accelerate the development and review of medical devices that may provide more effective diagnosis or treatment for serious or irreversibly debilitating conditions. Devices receiving this designation can benefit from priority review and more interactive communication with FDA experts during development and regulatory assessment. For Biostream, the designation provides an opportunity to engage with the agency as it advances the iNPH test towards clinical validation. Importantly, Breakthrough Device Designation is not FDA clearance or approval, does not establish that a device is clinically effective and does not guarantee future marketing authorization. The test remains investigational and is not currently available for commercial sale in the United States. Biostream plans to conduct a prospective clinical validation study at academic medical centres in the United States during 2027. This study is expected to be an important step in evaluating the test’s performance in patients undergoing assessment for suspected iNPH. Prospective validation will help determine how accurately the urine-based biomarker panel distinguishes iNPH from other neurological conditions and how the results may complement existing diagnostic methods. The company, founded in 2025, combines urinary protein analysis and machine learning to develop non-invasive diagnostic tools for neurological care. Its first product focuses on normal pressure hydrocephalus, an area where earlier recognition could potentially help patients access appropriate evaluation and treatment.
The announcement highlights the growing role of non-invasive biomarker diagnostics in neurological healthcare. If future clinical studies demonstrate reliable diagnostic performance, Biostream’s technology could provide clinicians with an additional tool for identifying patients who may benefit from specialist assessment. The planned 2027 validation programme will be critical in determining whether the investigational test can fulfil this potential and progress towards regulatory authorization.
Source: Biostream press release



